PERADES: Defining Genetic, Polygenic and Environmental Risk for Alzheimer's Disease using multiple powerful cohorts, focussed Epigenetics and Stem

Lead Research Organisation: Cardiff University
Department Name: School of Medicine

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Organisations

Publications

10 25 50
 
Description Academy Medical Sciences Council Member
Geographic Reach National 
Policy Influence Type Membership of a guideline committee
 
Description Academy Medical Sciences Fellow
Geographic Reach Multiple continents/international 
Policy Influence Type Membership of a guideline committee
 
Description Academy Medical Sciences Wales Ambassador
Geographic Reach National 
Policy Influence Type Membership of a guideline committee
 
Description Associate Director, UK Dementia Research Institute (UKDRI)
Geographic Reach Multiple continents/international 
Policy Influence Type Membership of a guideline committee
 
Description COVID advisory group
Geographic Reach National 
Policy Influence Type Membership of a guideline committee
 
Description Chief Scientific Advisor, Welsh Government
Geographic Reach Multiple continents/international 
Policy Influence Type Membership of a guideline committee
 
Description Deputy Director DPUK
Geographic Reach Local/Municipal/Regional 
Policy Influence Type Membership of a guideline committee
 
Description EPAD LCS sample access committe
Geographic Reach Multiple continents/international 
Policy Influence Type Membership of a guideline committee
 
Description Medicines Discovery Institute MDI
Geographic Reach National 
Policy Influence Type Membership of a guideline committee
 
Description NMHRI management
Geographic Reach National 
Policy Influence Type Membership of a guideline committee
 
Description A high content analysis platform for analysing dementia-associated genetic variation
Amount £108,300 (GBP)
Funding ID ARUK-EG2017A-1 
Organisation Alzheimer's Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2017 
End 09/2017
 
Description Centre for Ageing and Dementia Research (CADR)
Amount £1,200,000 (GBP)
Funding ID 507827 
Organisation Welsh Assembly 
Sector Public
Country United Kingdom
Start 04/2015 
End 03/2018
 
Description Centre for Ageing and Dementia Research - 2 Year Extension
Amount £1,200,000 (GBP)
Funding ID 514840 
Organisation Government of Wales 
Sector Public
Country United Kingdom
Start 04/2018 
End 03/2020
 
Description The development and implementation of polygenic risk algorithms for stratifying individuals for future cognitive decline due to Alzheimers disease
Amount £298,040 (GBP)
Funding ID 2018/20180222 
Organisation Innovate UK 
Sector Public
Country United Kingdom
Start 03/2018 
End 03/2020
 
Description Therapeutic targeting of impaired lysosomal flux in Alzheimer's disease
Amount £136,502 (GBP)
Funding ID MR/P007651/1 
Organisation Network of Centres of Excellence in Neurodegeneration (COEN) 
Sector Public
Country United Kingdom
Start 08/2016 
End 10/2017
 
Title AD Genetics Scotland 
Description Blood samples are collected from participants and sent directly from research sites to European Collection of Authenticated Cell Cultures (ECACC), a Culture Collection of Public Health England. Upon arrival, ECACC process the blood and transform into cell lines- peripheral blood lymphocytes (PBLs) and Lymphoblastoid cell lines (LCLs). Cell lines are frozen and stored at ECACC until they are required by the team at Cardiff. 
Type Of Material Biological samples 
Year Produced 2018 
Provided To Others? No  
Impact Ongoing collection of samples, no publications to date. 
 
Title DLB Genetics 
Description Blood samples are collected from participants and sent directly from research sites to European Collection of Authenticated Cell Cultures (ECACC), a Culture Collection of Public Health England. Upon arrival, ECACC process the blood and transform into cell lines- peripheral blood lymphocytes (PBLs) and Lymphoblastoid cell lines (LCLs). Cell lines are frozen and stored at ECACC until they are required by the team at Cardiff 
Type Of Material Biological samples 
Year Produced 2018 
Provided To Others? No  
Impact Ongoing collection of samples, no publications to date 
 
Title EOAD cohort 
Description We are collecting a biological sample of early onset Alzheimer's disease individuals for research. This includes phenotypic data and biological data and is set to become the largest EOAD biobank in the world. 
Type Of Material Biological samples 
Provided To Others? No  
Impact This earlier more aggressive form of the disease will be studied in order to shed light on disease mechanisms and prospective therapies. 
 
Title Plcg2 animal models 
Description To establish a functional pipeline for the study of disease associated genes and polymorphism in microglia and MØ in the context of dementia-related disease in vivo. The initial concentration is on the impact of coding mutations of PLCG2. In parallel, studies were initated on SPI1 and ABI3. Large scale 'omic and functional assay data derived from these studies will be used to bioinformatically identify potential causative abnormalities, by association with patient data 
Type Of Material Model of mechanisms or symptoms - mammalian in vivo 
Year Produced 2018 
Provided To Others? No  
Impact n/a 
 
Title Polygenic score 
Description With 80,000 variants included to create a measure of risk of Alzheimer's disease, the polygenic score is an excellent predictive tool to determine case/control status with high accuracy. The polygenic score encompasses the majority of genetic risk of disease, and can be fine-tuned to identify the pathways involved in disease, for example, immune cell activity or endocytosis. 
Type Of Material Model of mechanisms or symptoms - human 
Year Produced 2016 
Provided To Others? Yes  
Impact We are working to translate this method from the basic science environment in which it was created into a predictive tool used to select participants for clinical trials, based on their disease status and type. We are currently in discussions with a number of potential collaborators to take this forward. 
 
Title GERAD Exome chip data 
Description Dataset from Illumina Exome chip platform (version 1.0 and v1.1), approximately 6,000 cases and 4,000 controls 
Type Of Material Database/Collection of data 
Year Produced 2014 
Provided To Others? Yes  
Impact papers in press 
 
Description ADES Collaboration 
Organisation Erasmus MC
Country Netherlands 
Sector Hospitals 
PI Contribution A way to make aware our different institutions and funders of that we are working hard to a better organisation of the AD genetic field worldwide and we need strong support for this.
Collaborator Contribution as above
Impact n/a
Start Year 2016
 
Description ADES Collaboration 
Organisation Hospital de Sant Pau
Country Spain 
Sector Hospitals 
PI Contribution A way to make aware our different institutions and funders of that we are working hard to a better organisation of the AD genetic field worldwide and we need strong support for this.
Collaborator Contribution as above
Impact n/a
Start Year 2016
 
Description ADES Collaboration 
Organisation National Institute of Health and Medical Research (INSERM)
Country France 
Sector Academic/University 
PI Contribution A way to make aware our different institutions and funders of that we are working hard to a better organisation of the AD genetic field worldwide and we need strong support for this.
Collaborator Contribution as above
Impact n/a
Start Year 2016
 
Description ADES Collaboration 
Organisation Pasteur Institute, Lille
Country France 
Sector Charity/Non Profit 
PI Contribution A way to make aware our different institutions and funders of that we are working hard to a better organisation of the AD genetic field worldwide and we need strong support for this.
Collaborator Contribution as above
Impact n/a
Start Year 2016
 
Description ADES Collaboration 
Organisation University College London
Country United Kingdom 
Sector Academic/University 
PI Contribution A way to make aware our different institutions and funders of that we are working hard to a better organisation of the AD genetic field worldwide and we need strong support for this.
Collaborator Contribution as above
Impact n/a
Start Year 2016
 
Description ADES Collaboration 
Organisation University of Bonn
Country Germany 
Sector Academic/University 
PI Contribution A way to make aware our different institutions and funders of that we are working hard to a better organisation of the AD genetic field worldwide and we need strong support for this.
Collaborator Contribution as above
Impact n/a
Start Year 2016
 
Description ADES Collaboration 
Organisation University of Pennsylvania
Country United States 
Sector Academic/University 
PI Contribution A way to make aware our different institutions and funders of that we are working hard to a better organisation of the AD genetic field worldwide and we need strong support for this.
Collaborator Contribution as above
Impact n/a
Start Year 2016
 
Description ADES Collaboration 
Organisation VU University Medical Center
Country Netherlands 
Sector Academic/University 
PI Contribution A way to make aware our different institutions and funders of that we are working hard to a better organisation of the AD genetic field worldwide and we need strong support for this.
Collaborator Contribution as above
Impact n/a
Start Year 2016
 
Description CADR 
Organisation Bangor University
Country United Kingdom 
Sector Academic/University 
PI Contribution sample preparation, data analysis
Collaborator Contribution data analysis, sample collections
Impact none yet
Start Year 2014
 
Description CADR 
Organisation Swansea University
Country United Kingdom 
Sector Academic/University 
PI Contribution sample preparation, data analysis
Collaborator Contribution data analysis, sample collections
Impact none yet
Start Year 2014
 
Description CFAS 
Organisation Bangor University
Country United Kingdom 
Sector Academic/University 
PI Contribution We are working together with CFAS to prepare the 3,000 participant cohort for genetic research.
Collaborator Contribution Provided cohort
Impact CFAS prepared for Genetic analysis
Start Year 2009
 
Description CFAS 
Organisation Swansea University
Country United Kingdom 
Sector Academic/University 
PI Contribution We are working together with CFAS to prepare the 3,000 participant cohort for genetic research.
Collaborator Contribution Provided cohort
Impact CFAS prepared for Genetic analysis
Start Year 2009
 
Description EPAD 
Organisation GlaxoSmithKline (GSK)
Department Epidemiology
Country United Kingdom 
Sector Private 
PI Contribution GENOTYPING AND ANALYSIS
Collaborator Contribution cohorts, biomarker studies, epidemiological studies, random control studies
Impact none yet
Start Year 2014
 
Description Eisai Collaboration 
Organisation Eisai Ltd
Country Japan 
Sector Private 
PI Contribution We are identifying important genes and pathways involved in Alzheimer's disease for further investigation in functional experiments and drug-based tests.
Collaborator Contribution Expertise in functional biology
Impact None yet
Start Year 2015
 
Description GENAROAD 
Organisation Genetic Architecture of Rate of Alzheimer’s Decline (GENAROAD) Consortium
Country Global 
Sector Charity/Non Profit 
PI Contribution data and analyses
Collaborator Contribution data analysis
Impact none yet, paper being prepared for publication
Start Year 2013
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation Albert Ludwig University of Freiburg
Country Germany 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation Brigham Young University
Country United States 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation Central Institute for Mental Health
Country Germany 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation Free University of Berlin
Country Germany 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation Friedrich-Alexander University Erlangen-Nuremberg
Department Department of Psychiatry
Country Germany 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation German Centre for Neurodegenerative Diseases
Country Germany 
Sector Public 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation Goethe University Frankfurt
Country Germany 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation Helmholtz Association of German Research Centres
Department Helmholtz Zentrum Munchen
Country Germany 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation King's College London
Department Institute of Psychiatry, Psychology & Neuroscience
Country United Kingdom 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation Ludwig Maximilian University of Munich (LMU Munich)
Department Department of Neurology
Country Germany 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation Mayo Foundation for Medical Education and Research (MFMER)
Country United States 
Sector Charity/Non Profit 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation Medical Research Council (MRC)
Department MRC Centre for Neuropsychiatric Genetics and Genomics
Country United Kingdom 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation National Institutes of Health (NIH)
Country United States 
Sector Public 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation Oxford University Hospitals NHS Foundation Trust
Department NIHR Oxford Biomedical Research Centre
Country United Kingdom 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation Queen's University Belfast
Department Aging group
Country United Kingdom 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation The Wellcome Trust Sanger Institute
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation Trinity College Dublin
Country Ireland 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation University College London
Department Institute of Neurology
Country United Kingdom 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation University College London
Department MRC Prion Unit and the Dementia Research Centre
Country United Kingdom 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation University Duisburg-Essen
Country Germany 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation University of Bonn
Department Department of Psychiatry
Country Germany 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation University of Bristol
Department Dementia Research Group
Country United Kingdom 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation University of Cambridge
Department Cambridge Institute of Public Health
Country United Kingdom 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation University of Hamburg
Country Germany 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation University of Manchester
Department Neuroscience Research Institute (NRI)
Country United Kingdom 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation University of Nottingham
Department Centre for Genetics and Genomics
Country United Kingdom 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation University of Southampton
Department Clinical and Experimental Sciences
Country United Kingdom 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation University of Zurich
Department Functional Genomics Centre Zurich
Country Switzerland 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation Washington University in St Louis
Country United States 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description Genome-wide Association Studies 
Organisation National Center for Biotechnology Information (NCBI)
Country United States 
Sector Public 
PI Contribution Led and co-ordinated the study that involved the work of the following collaborators: 1 MRC Centre for Neuropsychiatric Genetics and Genomics, Department of Psychological Medicine and Neurology, School of Medicine, Cardiff University, Cardiff CF14 4XN, UK. 2 NIHR Biomedical Research Centre for Mental Health at the South London and Maudsley NHS Foundation Trust and Institute of Psychiatry, Kings College, London, UK. 3 Department of Neuroscience, Institute of Psychiatry, Kings College, London, UK. 4 Institute of Public Health, University of Cambridge, Cambridge, UK. 5 Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK. 6 Mercer's Institute for Research on Aging, St. James Hospital and Trinity College, Dublin, Ireland. 7 Institute of Genetics, Queen's Medical Centre, University of Nottingham, NG7 2UH, UK. 8 Ageing Group, Centre for Public Health, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, UK. 9 Division of Clinical Neurosciences, School of Medicine, University of Southampton, Southampton, UK. 10 Clinical Neuroscience Research Group, Greater Manchester Neurosciences Centre, University of Manchester, Salford, UK. 11 Oxford Project to Investigate Memory and Ageing (OPTIMA), University of Oxford, Level 4, John Radcliffe Hospital, Oxford OX3 9DU, UK. 12 Dementia Research Group, University of Bristol Institute of Clinical Neurosciences, Frenchay Hospital, Bristol, UK. 13 Department of Molecular Neuroscience and Reta Lilla Weston Laboratories, Institute of Neurology, London, UK. 14 MRC Prion Unit, Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK. 15 Dementia Research Centre, Department of Neurodegenerative Diseases, University College London, Institute of Neurology, London, UK. 16 Department of Psychiatry, University of Bonn, Sigmund-Freud-Str. 25, D-53105 Bonn, Germany. 17 Institute of Primary Medical Care, University Medical Center Hamburg-Eppendorf, Germany. 18 Department of Psychiatry, Charité Berlin, Germany. 19 Department of Psychiatry and Psychotherapy, University of Erlangen-Nüremberg, Germany. 20 LVR-Hospital Essen, Department of Psychiatry and Psychotherapy, University Duisburg-Essen, Germany. 21 Institute for Stroke and Dementia Reserach, Klinikum der Universität München, Marchioninistr. 15, 81377, Munich, Germany. 22 Department of Neurology, Klinikum der Universität München, Marchioninistr. 15, 81377, Munich, Germany. 23 Department of Geriatric Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Square J5, D-68161 Mannheim, Germany. 24 Discipline of Psychiatry, School of Medicine and Trinity College Institute of Neuroscience, Laboratory of Neuroimaging & Biomarker Research, Trinity College, University of Dublin, Ireland. 25 Alzheimer Memorial Center and Geriatric Psychiatry Branch, Department of Psychiatry, Ludwig-Maximilian University, Munich, Germany. 26 Centre for Geriatric Medicine and Section of Gerontopsychiatry and Neuropsychology, Medical School, University of Freiburg, Germany. 27 Departments of Psychiatry, Neurology and Genetics, Washington University School of Medicine, St Louis, MO 63110, US. 28 Department of Biology, Brigham Young University, Provo, UT, 84602, USA. 29 Neurodegenerative Brain Diseases group, Department of Molecular Genetics, VIB, Antwerpen, Belgium. 30 Institute Born-Bunge and University of Antwerp; Antwerpen, Belgium. 31 Memory Clinic and Department of Neurology, ZNA Middelheim, Antwerpen, Belgium. 32 Department of Mental Health Sciences, University College London, UK. 33 The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK. 34 MRC Centre for Neurodegeneration Research, Department of Clinical Neuroscience, King's College London, Institute of Psychiatry, London, SE5 8AF, UK. 35 3rd Department of Neurology, Aristotle University of Thessaloniki, Thessaloniki, Greece. 36 Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, 20892, USA. 37 Department of Genomics, Life & Brain Center, University of Bonn, Sigmund-Freud-Str. 25, D-53127 Bonn, Germany. 38 Institute of Human Genetics, University of Bonn, Wilhelmstr. 31, D-53111 Bonn, Germany. 39 Institute for Medical Informatics, Biometry and Epidemiology, University Hospital of Essen, University Duisburg-Essen, Hufelandstr. 55, D-45147 Essen, Germany. 40 Institute of Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, 85764 Neuherberg, Germany. 41 Institute of Medical Informatics, Biometry and Epidemiology, Chair of Epidemiology, Ludwig-Maximilians-Universität, Munich, Germany. 42 Department of Neuroscience, Mayo Clinic College of Medicine, Jacksonville, Florida 32224, USA. 43 Division of Biomedical Statistics and Informatics, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
Collaborator Contribution This group of 45 collaborators all contributed towards the centres Genome-wide association study
Impact The study, published in Nature Genetics (PubMed ID 19734902), has uncovered two new genes associated with Alzheimer's disease. Previously only one gene, APOE4, had been shown to be a risk factor for Alzheimer's disease. The study reveals, for the first time, that two further genes, CLU and PICALM, are related to Alzheimer's disease. This has led to worldwide media coverage. The data produced is still used in new studies with requests coming in to the host institution every few weeks.
Start Year 2009
 
Description Genomics England 
Organisation Genomics England
Country United Kingdom 
Sector Public 
PI Contribution We are in the very early stages of discussion with Genomics England, but we hope to be able to use their facilities for whole Genome sequencing. This will mean that we generate valuable data on the largest EOAD cohort world-wide.
Collaborator Contribution Genomics England have the equipment and infrastructure set up for the very expensive and technical whole exome sequencing.
Impact None yet
Start Year 2015
 
Description GlaxoSmithKline Cardiff Collaboration 
Organisation GlaxoSmithKline (GSK)
Country Global 
Sector Private 
PI Contribution Prof Williams made contact with a GSK rep at the Global Genetics Congress in Baltimore, September 2016. GSK were extremely interested in collaborating with the Cardiff team. Specifically, GSK have an interest in the latest confidential experimental results and translating these from genetic to biological meaning. This will speed up the Cardiff Team's discovery of potential molecular targets for personalised disease treatment. Cardiff will contribute expertise in Alzheimer's disease genetics.
Collaborator Contribution GSK will contribute their expertise in disease models and drug mechanisms.
Impact This collaboration has been brought under a confidentiality agreement. Parties involved are experts in genetics and functional biology.
Start Year 2016
 
Description Jackson labs collaboration 
Organisation The Jackson Laboratory
Country United States 
Sector Charity/Non Profit 
PI Contribution We provide the most up to date genetic human Alzheimer's disease study results and interpretation.
Collaborator Contribution Jackson labs provide their expertise in translation of human study findings into small animal transgenic models of genetic diseases.
Impact Attempts so far to tie down both a project plan and committed funding, have not been successful. We are currently exploring alternative methods to whole animal experiments. We hope that in the future we will be able to regenerate interest in this promising collaboration.
Start Year 2016
 
Description MRC AD Cohort 
Organisation King's College London
Department Institute of Psychiatry, Psychology & Neuroscience
Country United Kingdom 
Sector Academic/University 
PI Contribution We contributed DNA, clinical follow up information, genotyping and other laboratory work and complex data analysis.
Collaborator Contribution The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.
Impact 16970641 17322133 17530621 17440948 17440933 17373700 17999207 18163421
 
Description MRC AD Cohort 
Organisation Medical Research Council (MRC)
Department MRC Centre for Developmental Neurobiology
Country United Kingdom 
Sector Academic/University 
PI Contribution We contributed DNA, clinical follow up information, genotyping and other laboratory work and complex data analysis.
Collaborator Contribution The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.
Impact 16970641 17322133 17530621 17440948 17440933 17373700 17999207 18163421
 
Description MRC AD Cohort 
Organisation Trinity College Dublin
Country Ireland 
Sector Academic/University 
PI Contribution We contributed DNA, clinical follow up information, genotyping and other laboratory work and complex data analysis.
Collaborator Contribution The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.
Impact 16970641 17322133 17530621 17440948 17440933 17373700 17999207 18163421
 
Description MRC AD Cohort 
Organisation University of Cambridge
Department Department of Medical Genetics
Country United Kingdom 
Sector Academic/University 
PI Contribution We contributed DNA, clinical follow up information, genotyping and other laboratory work and complex data analysis.
Collaborator Contribution The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.
Impact 16970641 17322133 17530621 17440948 17440933 17373700 17999207 18163421
 
Description MRC AD Cohort 
Organisation University of Cambridge
Department Department of Public Health and Primary Care
Country United Kingdom 
Sector Academic/University 
PI Contribution We contributed DNA, clinical follow up information, genotyping and other laboratory work and complex data analysis.
Collaborator Contribution The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.
Impact 16970641 17322133 17530621 17440948 17440933 17373700 17999207 18163421
 
Description PROTECT / CHARIOT-Pro / Cardiff DPUK 
Organisation Imperial College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Genotyping of 1,000 research participants from the PROTECT (KCL & Exeter) and CHARIOT - Pro (Imperial) research studies will be completed by Cardiff Univ as part of a collaboration funded by Dementias Platform UK. Polygenic risk scores will be calculated for these individuals and data made available via DPUK Platform.
Collaborator Contribution DNA samples from 1,000 research participants from the PROTECT (KCL & Exeter) and CHARIOT - Pro (Imperial) research studies will be sent to Cardiff Univ for genotyping
Impact None to date - work in progress. Collaboration is multi-disciplinary - Neurology, Neuroepidemiology & Ageing; Genetics & Genomics; Psychiatry
Start Year 2018
 
Description PROTECT / CHARIOT-Pro / Cardiff DPUK 
Organisation King's College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Genotyping of 1,000 research participants from the PROTECT (KCL & Exeter) and CHARIOT - Pro (Imperial) research studies will be completed by Cardiff Univ as part of a collaboration funded by Dementias Platform UK. Polygenic risk scores will be calculated for these individuals and data made available via DPUK Platform.
Collaborator Contribution DNA samples from 1,000 research participants from the PROTECT (KCL & Exeter) and CHARIOT - Pro (Imperial) research studies will be sent to Cardiff Univ for genotyping
Impact None to date - work in progress. Collaboration is multi-disciplinary - Neurology, Neuroepidemiology & Ageing; Genetics & Genomics; Psychiatry
Start Year 2018
 
Description PROTECT / CHARIOT-Pro / Cardiff DPUK 
Organisation University of Exeter
Country United Kingdom 
Sector Academic/University 
PI Contribution Genotyping of 1,000 research participants from the PROTECT (KCL & Exeter) and CHARIOT - Pro (Imperial) research studies will be completed by Cardiff Univ as part of a collaboration funded by Dementias Platform UK. Polygenic risk scores will be calculated for these individuals and data made available via DPUK Platform.
Collaborator Contribution DNA samples from 1,000 research participants from the PROTECT (KCL & Exeter) and CHARIOT - Pro (Imperial) research studies will be sent to Cardiff Univ for genotyping
Impact None to date - work in progress. Collaboration is multi-disciplinary - Neurology, Neuroepidemiology & Ageing; Genetics & Genomics; Psychiatry
Start Year 2018
 
Title DIAGNOSIS AND TREATMENT OF ALZHEIMER'S DISEASE 
Description The invention relates to novel variants that associate with Alzheimer's disease AD and their use in kits as a means for diagnosing AD; and also their use in nucleic acid molecules or cells/cell lines for identifying novel therapeutic, label of identification means. 
IP Reference WO2011001135 
Protection Patent granted
Year Protection Granted 2011
Licensed No
Impact This has had huge worldwide impact through media coverage and was originally highlighted in the press with the discovery of an additional 5 genes. We are currently in the process of seeking a licencee for the patented technology which encompasses a diagnostic test for the protected gene SNPs. Recent advances include generation of a polygenic score including the licensed SNPs for the detection of AD risk. We are working together with industry on basic genetic testing, cohort studies, cognitive te
 
Description AAIC Los Angeles Annual Conference 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact MODEL-AD presentation - Alzheimer's Susceptibility Genes Implicate Microglial Activity
Year(s) Of Engagement Activity 2019
 
Description AMS fellowship workshop 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Other audiences
Results and Impact Organisation of a Academy of Medical Science workshop by J Williams as Wales AMS Champion to encourage applications from young researchers to become AMS fellows
Year(s) Of Engagement Activity 2019
 
Description ARUK Conference 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact Attendee at online conference
Year(s) Of Engagement Activity 2022
 
Description ARUK network 2019 Exeter 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Other audiences
Results and Impact The event was organised between the ARUK Bristol & Bath, Southwest (Exeter and Plymouth) and Wales networks. The aim was for members to meet, showcase research & build collaborations. J Williams spoke on Research infrastructure and resources: UKDRI as member of Cardiff University and UK Brain Banks Network
Year(s) Of Engagement Activity 2019
 
Description Alzheimer's gene study achieves landmark breakthrough 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Media (as a channel to the public)
Results and Impact Cardiff University publicised publication in Nature Genetics "Genetic meta-analysis of diagnosed Alzheimer's disease identifies novel risk loci and implicates Abeta, Tau, immunity and lipid processing" - aiming to raise public awareness of research being undertaken at UK Dementia Research Institute Cardiff
Year(s) Of Engagement Activity 2019
 
Description BBC Wales evening news UK DRI Cardiff official opening 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Interview of Professor Julie Williams to publicise official opening of UK DRI Cardiff. Prof Williams explained the purpose of the DRI, its multi-targeted approach, and the funding that had enabled attraction of world class scientists to Cardiff.
Year(s) Of Engagement Activity 2018
URL https://www.bbc.co.uk/iplayer/episode/b0bp0k0t/bbc-wales-today-evening-news-25102018#
 
Description BBC radio interview 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Media (as a channel to the public)
Results and Impact Radio interview BBC Forty research groups led by scientists in Cardiff, France and the United States have been working more closely together and have now pooled a worldwide database of 90,000 samples. "We're about to submit a paper that is enormously exciting and which I think will really change, without a doubt, what we think of Alzheimer's disease going forward," Professor Julie Williams, head of the research team at Cardiff University, said. "Over the last five or six years we've been successful in identifying 30 genes that increase - or decrease - your risk for Alzheimer's disease. Now this is telling us what some of the major components in disease development are. It's new, it's exciting; it's a different perspective on what Alzheimer's disease is."
Year(s) Of Engagement Activity 2018
URL http://www.bbc.co.uk/news/uk-wales-36286847
 
Description Best Paper of 2022 meeting 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Media (as a channel to the public)
Results and Impact Meeting to discuss paper that was deemed the best of 2022
Year(s) Of Engagement Activity 2022
 
Description Brain Conference 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Industry/Business
Results and Impact Invited speaker
Year(s) Of Engagement Activity 2022
 
Description Brain Conference 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Industry/Business
Results and Impact The Guarantors of Brain was set up to promote teaching, education and research in neurology and related disciplines. In 2021, we put on our first conference - run as a 2-day online conference, with a focus on clinical neurology and research. The conference was attended by almost 2000 delegates across the globe.
Year(s) Of Engagement Activity 2022
 
Description CURE ND Workshop 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact Workshop to discuss disease models in the field of neurodegeneration, what are the most advanced models to date, how accurate are they, and what is missing in terms of modelling
Year(s) Of Engagement Activity 2021
 
Description Cheltenham Science Festival 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact The Festival theme 2019 was health and wellbeing, considering everything from the food we eat and our exercise regimes to cutting-edge medical research. As part of this theme, the event explored the latest breakthroughs in dementia research. The panel was asked to talk about the broad landscape in this field and its evolution in recent years, key achievements and challenges and an insight into how the diagnosis and treatment of dementia has changed and developed. J Williams talked about cutting-edge research and expertise and the exciting aspects of her own work within this area
As populations have aged, dementia has become the fifth biggest cause of death worldwide. Yet despite its devastating consequences there is currently no cure. What do we know about this group of diseases, and are there things we can do to help reduce our risks and keep our brains fighting fit? Alzheimer's disease specialist Julie Williams and psychiatrist Ivan Koychev discuss the latest breakthroughs and discoveries that are helping to prevent, diagnose and treat dementia more effectively.
Year(s) Of Engagement Activity 2011,2019
 
Description Insurance United Against Dementia 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Supporters
Results and Impact Alzheimer's Society Insurance United Against Dementia campaign dinner - aim to formally launch IUAD partners to senior figureheads from the insurance industry Used as an opportunity to thank existing IUAD partners and inspire potential partners to make a contribution.
Year(s) Of Engagement Activity 2019
 
Description Interview for national news 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Media (as a channel to the public)
Results and Impact Interview on national TV which is broadcast worldwide describing set up of Cardiff Univ receiving funding to set up as a UK dementia centre
Year(s) Of Engagement Activity 2018
URL http://www.bbc.co.uk/news/uk-wales-south-east-wales-39646667
 
Description Interview for national news 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Official opening of UK DRI Cardiff, attended by 300+ guests, including funders, Welsh government officials, members of the public taking part in dementia research studies, postgraduates. Widely publicised on national BBC and ITV news and radio
Year(s) Of Engagement Activity 2018
URL https://www.bbc.co.uk/news/uk-wales-45942094
 
Description Interview for regional news 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Media (as a channel to the public)
Results and Impact Interview on regional news to discuss setting up of new DRI UK laboratories in Cardiff and work on dementia research
Year(s) Of Engagement Activity 2018
URL http://www.itv.com/news/wales/2017-04-20/dementia-centre-to-offer-step-change-in-research/
 
Description Interview with BBC 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact Interview with BBC - Alzheimer's article
Year(s) Of Engagement Activity 2022
 
Description Keynote speech Sutcliffe Kerr Lecture 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Other audiences
Results and Impact Keynote speech at annual Walton Centre, Sutcliffe Kerr Lecture
Year(s) Of Engagement Activity 2019
 
Description Local news item on brain donation for dementia research 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Older people in Wales are being urged to think about donating their brains after they die to help scientists researching dementia. This has sparked questions and debates - 80 comments within 24 hours. It will definitely influence people by raising awareness of the disease, the process of donation, benefits of donation/research and also opting in/out law change. We are confident this will increase the number of healthy/diseased donations and positively impact research field.
Year(s) Of Engagement Activity 2018
URL http://www.bbc.co.uk/news/uk-wales-43084710
 
Description MRC CNGG celebration event 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact MRC CNGG celebration - presentation and video
Year(s) Of Engagement Activity 2019
 
Description Medical Women's Federation Spring Conference 2018 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Presentation on 'Finding the causes of Alzheimer's disease'
Year(s) Of Engagement Activity 2018
 
Description Quote for This is Wales publication 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Quotation provided on the subject of innovation in Wales for trade magazine, emphasising research focus on dementia, specifically Alzheimer's disease
Year(s) Of Engagement Activity 2018
 
Description RCPsych Neuropsychiatry Annual Conference 2019 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Talk given to conference entitled "Neuropsychiatric Genetics of Dementia and other Neurodegenerative Disorders: Implications for treatment, prevention and personalised psychiatry"
Year(s) Of Engagement Activity 2019
 
Description Radio Interview with Alz Res UK Champion 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Radio Gloucester interview with Sue Strachan Alz Res UK Champion
Year(s) Of Engagement Activity 2021
 
Description Radio interview 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact Radio 4 interview for the programme The Life Scientific
Year(s) Of Engagement Activity 2023
 
Description Recorded interview ARUK conference March 2018 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact An interview with Video Journal Dementia at ARUK Conference 2018 discussing work at Cardiff DRI UK - online publication aimed at healthcare professionals
Year(s) Of Engagement Activity 2018
URL https://vjdementia.com/speaker/julie-williams
 
Description Taking a new look at the risk factors for Alzheimer's disease 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Media article on publication of Multiplex Model in Nature Neuroscience - providing information on how the genes that have been identified as risk factors impact on other genes to trigger Alzheimer's
Year(s) Of Engagement Activity 2020
 
Description Techniquest 55+Science Cafe Launch 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Supporters
Results and Impact Invited speaker
Year(s) Of Engagement Activity 2022
 
Description UK Biobank Winter Scientific Conference 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact Invited speaker to conference in London
Year(s) Of Engagement Activity 2022
 
Description UK Korea Neuroscience Symposium 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact UKorea symposia bridge basic and clinical research within neuroscience. J Williams gave plenary lecture on 1st day 2019 symposium. The statements were shared via the UK-Korea social media channel (twitter @UKorea_Neuro).
Year(s) Of Engagement Activity 2019
 
Description Visit by Lord Mayor of Cardiff to DRI 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Other audiences
Results and Impact Visit by Lord Mayor of Cardiff to Dementia Research Institute
Year(s) Of Engagement Activity 2022
 
Description Visit by Ruth Jones MP to DRi 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Other audiences
Results and Impact Ruth Jones MP visited Dementia Research Institute Cardiff
Year(s) Of Engagement Activity 2022
 
Description Visit of Jo Stephens MP to DRI 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Other audiences
Results and Impact Visit by Jo Stephens MP to Cardiff Dementia Research Institute
Year(s) Of Engagement Activity 2022
 
Description Visit to DRI laboratories by Sir Venki Ramakrishnan 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Other audiences
Results and Impact Sir Venki Ramakrishnan, the President of the Royal Society visited DRI laboratories, Cardiff on 23rd October prior to giving a lecture organised by Welsh Government
Year(s) Of Engagement Activity 2019
 
Description Welsh Government workshop 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Policymakers/politicians
Results and Impact The Welsh Government held a UKRI "Strength in Places Fund" and potential for Wales workshop. Strength in Places (SIP) offers a significant funding opportunity and the University is keen to prepare a pipeline of projects for development in this area, in what is anticipated, to be an annual call.
Year(s) Of Engagement Activity 2019
 
Description Will members of my family develop Alzheimers disease?' 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Dr Rebecca Sims presented "Will members of my family develop Alzheimer's disease?" at CADR Meeting Swansea, 2/8/2018. This reached an audience of 50 persons including general public, medical professionals, researchers and carers. This generated a number of questions and discussion after the talk, and was part of a wider discussion following other presentations focusing on similar topics.
Year(s) Of Engagement Activity 2018
 
Description Women in Industry 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Industry/Business
Results and Impact Presentation to Women in Industry event, providing overview of career, advice for women in STEM careers
Year(s) Of Engagement Activity 2019
 
Description Women in Science film 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Media (as a channel to the public)
Results and Impact Women in Science video as one of the interviewees / case studies.
Year(s) Of Engagement Activity 2019
 
Description World Dementia Conference - speaker 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact This WDC summit meeting was focused on 'Looking to the Future: The Dementia landscape' and followed the series of global dialogues as part of the WDC's dementia landscape project. Discussion took place on the science and research agenda and built on previous conversations of international dementia leaders around innovation and incentives and data sharing. As a guest speaker, asking the question 'are we on track', we explored whether the research and policy landscape facilitating the development of new treatments required global co-ordination, considered whether the right things are being funded and whether new funding models were required.
Year(s) Of Engagement Activity 2021
 
Description World Dementia Council 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact Speaker
Year(s) Of Engagement Activity 2022